Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: ValuEngine, Inc.
$49.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

AbbVie Inc's Hepatitis C Treatment Helps 96% Of Patients In Trial - Reuters


Monday, 18 Nov 2013 08:57am EST 

Reuters reported that AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96% of patients had no detectable levels of the virus after 12 weeks. The trial is being watched closely because of the potential of the treatment, 3D regimen, to obviate the need for the injectable drug interferon, which can have debilitating side effects. The trial, named Sapphire-I, is the first of six late-stage trials testing AbbVie's interferon-free treatment.